An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
|Articles|April 5, 2022
Daily OTC Pearl: Lidocaine Pain Relief
Author(s)Saro Arakelians, PharmD
Lidocaine is a local anesthetic that offers temporary relief of pain and itching.
Advertisement
OTC/Lifestyle Pearl of the Day: Lidocaine Pain Relief
Indication: Lidocaine is alocal anesthetic that offerstemporary relief of pain and itching.It prevents pain by blocking the signals at the nerve endings in the skin.
Insight:
- Active ingredient: Lidocaine HCI 4%
- Inactive ingredients: Acrylates/C10-30 alkyl acrylate crosspolymer, aloe barbadensis leaf juice, aminomethyl propanol, C30-45 alkyl cetearyl dimethicone crosspolymer, caprylyl methicone, cetearyl alcohol, ceteth-20 phosphate, dicetyl phosphate, dimethicone, disodium EDTA, ethylhexylglycerin, glyceryl stearate, methylparaben, SD alcohol 40, steareth-21, water.
- Directions: In adults and children 2 years of age and older, apply to affected area no more than 3 to 4 times daily. For children under 2 years of age, consult a physician.
- Warnings: For external use only. When using this product, use only as directed.
- Avoid contact with eyes.
- Do not use in large quantities, particularly over raw surfaces or blistered areas.
- Stop use and ask a physician if condition worsens, if symptoms persist for more than 7 days, or clear up and occur again within a few days.
- Keep out of reach of children.
- If swallowed, get medical help or contact a poison control center immediately.
Source:
Advertisement
Related to this article
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5